ChronoScale has formally classified its legacy Ekso Bionics exoskeleton business as held for sale and discontinued operations, putting one of the industry’s longest-running names on course for another ownership change.
The classification appears in ChronoScale Holdings Corporation’s annual report signed on 19 August 2026. It does not represent a newly announced decision to sell Ekso: the company says its board committed to a divestiture plan on 29 May and publicly announced that plan on 4 June. What the new filing adds is a clearer accounting and strategic picture of where the exoskeleton operation now sits inside ChronoScale.
ChronoScale says it expects the divestiture to be completed during fiscal year 2027. No buyer, purchase price or transaction structure has been disclosed.
At a glance
- Business: Legacy Ekso Bionics exoskeleton operation.
- Current classification: Held for sale and discontinued operations.
- Board decision: 29 May 2026.
- Public divestiture announcement: 4 June 2026.
- Expected timing: ChronoScale says it expects a sale during fiscal year 2027.
- Potential buyer: Not disclosed.
- Strategic direction: ChronoScale intends to focus on its cloud-computing business.
The August filing formalizes Ekso’s separation from ChronoScale
Ekso Bionics entered 2026 as one of the best-known publicly traded names associated directly with exoskeleton technology.
That structure changed substantially in May when Ekso’s public parent completed a business combination involving Applied Digital Cloud. The continuing public company became ChronoScale, while the legacy exoskeleton operation continued through Ekso Bionics, Inc.
The latest annual report makes the strategic separation unusually explicit.
ChronoScale states that the Legacy Ekso Business met the accounting criteria to be classified as held for sale and that its operating results are now reported separately as discontinued operations. The company says the planned sale reflects its decision to focus operations solely on its cloud business.
This distinction matters. Ekso Bionics continues to represent an operating exoskeleton business, but it should no longer be interpreted as the core continuing business of the listed ChronoScale parent.
We already reflected that distinction in our broader 2026 exoskeleton market analysis, where Ekso is no longer treated as a clean public-market exoskeleton pure play.
The filing gives a clearer look at the business being separated
ChronoScale reported approximately US$19.84 million of current assets held for sale associated with Legacy Ekso as of 31 May 2026, against approximately US$5.03 million of liabilities held for sale.
The income statement requires more care.
The discontinued-operations table reports US$385,000 of revenue and a US$1.02 million net loss for Legacy Ekso. Those figures should not be interpreted as a full year of Ekso Bionics operating performance. The filing explains that the discontinued-operation results represent the period from the business-combination closing on 5 May through 31 May 2026.
That short measurement period makes the figures useful for understanding the accounting treatment, but not for estimating the normal annual revenue run-rate of the underlying exoskeleton business.
What could a buyer actually be acquiring?
Ekso Bionics has operated across several parts of the wearable-robotics market over its history.
Its current portfolio includes medical and personal-mobility technology such as the Ekso Indego Personal, alongside industrial products including the passive Ekso EVO.
The strategic value of an established exoskeleton company is not limited to the physical hardware.
A buyer could also be evaluating intellectual property, regulatory experience, clinical relationships, installed products, distribution, reimbursement knowledge, engineering capability and an established industry brand.
ChronoScale has not disclosed whether the business will be sold intact, whether specific assets could be separated, or what type of buyer is being targeted. Those questions therefore remain open.
Exoskeleton Index analysis
Ekso’s next owner matters because this is not a start-up with a single prototype. Ekso carries years of regulatory, clinical, industrial and product-development history. In a market where distribution, reimbursement, service and trusted institutional relationships increasingly matter alongside hardware performance, an established platform can be strategically valuable even when its recent financial performance is challenging.
Another sign of consolidation in wearable robotics
The planned Ekso divestiture fits a broader pattern emerging across the exoskeleton industry.
Specialist wearable-robotics companies increasingly interact with much larger medtech, industrial and technology groups through acquisitions, strategic investments, manufacturing partnerships and distribution agreements.
Ottobock acquired SUITX. Renault invested in Wandercraft and formed an industrial partnership around manufacturing. Large groups including Hyundai and Kia have developed exoskeleton platforms internally. Consumer companies are partnering with established outdoor and footwear brands.
That does not mean every exoskeleton company will be acquired. It does mean that intellectual property and specialist human-robot interaction expertise are increasingly becoming assets that larger organizations can integrate into broader platforms.
Ekso could become another important test of that thesis.
The sale does not mean the Ekso products disappear
“Held for sale” is an accounting and strategic classification. It is not an announcement that Ekso has stopped operating or that its products have been discontinued.
Current Exoskeleton Index records continue to classify relevant Ekso products according to the most recent public product information available to us.
That status should be reassessed as the transaction develops.
For hospitals, rehabilitation providers, distributors and industrial buyers, the practical questions will be whether product support, training, warranty arrangements, regulatory responsibilities and commercial relationships continue normally through and after any ownership transition.
What remains unknown
- Who is negotiating to acquire the Legacy Ekso Business.
- Whether there is already a preferred buyer.
- The expected transaction value.
- Whether the whole Ekso operation will transfer together.
- How the Ekso brand will be handled after a transaction.
- Whether the current product portfolio will change.
- What the transaction will mean for employees, distributors and clinical partners.
- The exact timing of the divestiture within fiscal year 2027.
The annual report itself also cautions that ChronoScale may not be able to complete the planned divestiture on acceptable terms or at all. The expected timing should therefore be treated as management’s current plan rather than a completed transaction.
Why this matters for the exoskeleton market
Ekso Bionics has been part of the modern exoskeleton industry for much longer than the current consumer boom.
Its transition from listed specialist, to part of a cloud-focused public-company transaction, and now toward a planned divestiture illustrates how quickly the corporate structure around wearable robotics is changing.
The next phase could be more important than the accounting classification itself.
If Ekso is acquired by a group with stronger distribution, healthcare infrastructure, capital or manufacturing capability, the transaction could give established exoskeleton technology a different route to scale. If the sale becomes prolonged or fragmented, it could instead create uncertainty around an important legacy platform.
For now, the most accurate conclusion is narrower: ChronoScale has formally separated Legacy Ekso from continuing operations and is actively planning its sale.
Explore the broader context in our Exoskeleton Market in 2026, browse exoskeleton companies, or review current systems in the Exoskeleton Index product directory.
Sources
- ChronoScale Holdings Corporation, Annual Report on Form 10-K for the fiscal year ended 31 May 2026, signed 19 August 2026.
- ChronoScale / Ekso Bionics business-combination filings, 2026.
- Exoskeleton Report, Week 34 newsletter archive, 24 August 2026.
- Exoskeleton Index product records for Ekso Indego Personal and Ekso EVO.
Editorial note: This article describes a corporate transaction process and is not investment advice. Transaction timing and completion remain subject to change.
